ABSTRACT
This chapter is an update of the chapter in the previous edition on targeted therapies in spondyloarthritides (SpA) and will only discuss studies that have been published since then. Recent years have confirmed the unique position of the tumor necrosis factor (TNF) blocking agents for the treatment of patients with SpA, especially in active ankylosing spondylitis (AS), while data on other forms of SpA are still quite limited.
